| P50 | author | Joanne Bowen | Q50228486 |
| | Micah Peters | Q57790662 |
| | Emma Bateman | Q86910073 |
| P2093 | author name string | J M Campbell | |
| | M D Stephenson | |
| | D M Keefe | |
| P2860 | cites work | UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer | Q24648015 |
| | Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study | Q24653790 |
| | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 |
| | Irinotecan pharmacogenomics | Q28287024 |
| | Replicating genotype-phenotype associations | Q29614919 |
| | Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management | Q30318822 |
| | Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey | Q33406703 |
| | Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. | Q33783293 |
| | Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer | Q33927990 |
| | Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. | Q34314677 |
| | Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. | Q34343197 |
| | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer | Q34565071 |
| | Effects of MTHFR genetic polymorphisms on toxicity and clinical response of irinotecan-based chemotherapy in patients with colorectal cancer | Q35115336 |
| | How do systematic reviews incorporate risk of bias assessments into the synthesis of evidence? A methodological study. | Q35496622 |
| | UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil | Q36450521 |
| | Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? | Q36816419 |
| | Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients | Q36943988 |
| | Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review | Q37345974 |
| | Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes | Q37378223 |
| | Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. | Q37495094 |
| | Impact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients | Q37577685 |
| | Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians | Q37712297 |
| | Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis | Q37718359 |
| | Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review | Q37953721 |
| | Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis | Q37964994 |
| | The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens | Q38005612 |
| | Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis | Q38016943 |
| | Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review | Q38075848 |
| | Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. | Q38146384 |
| | UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians | Q38180605 |
| | The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis | Q38202816 |
| | Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach | Q38584927 |
| | Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. | Q38740840 |
| | Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations | Q39489732 |
| | Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis | Q42285614 |
| | Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. | Q43102323 |
| | Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial | Q43254499 |
| | Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? | Q43843440 |
| | Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. | Q46007183 |
| | Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. | Q46926434 |
| | Pharmacogenetic and Germline Prognostic Markers of Lung Cancer | Q57896566 |
| | UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan | Q58408313 |
| | The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer | Q60697890 |
| | Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea | Q72065177 |
| | Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials | Q74251746 |
| | From bedside to bench to bedside to clinical practice: an odyssey with irinotecan | Q82903015 |
| | Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms | Q84526175 |
| | British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011 | Q84995099 |
| | Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy | Q85882709 |
| | Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients | Q87276774 |
| | The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer | Q87374369 |
| | Irinotecan pharmacogenetics: a finished puzzle? | Q88141471 |
| P433 | issue | 1 | |
| P921 | main subject | meta-analysis | Q815382 |
| | systematic review | Q1504425 |
| P304 | page(s) | 21-28 | |
| P577 | publication date | 2016-08-09 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses | |
| P478 | volume | 17 | |